Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world’s largest independent nonprofit research and development o...
Study conducted in collaboration with the Neuroregeneration Institute at McLean Hospital Autologous neuronal cell therapy for Parkinson’s diseas...
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrut...
Congruence Therapeutics announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-mole...
Curia, a leading contract research, development and manufacturing organization (CDMO), announced progress on the expansion at its Glasgow, UK sterile dru...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
— $9M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased Capacity for Suppository, Semi-Solid,...
TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s in...
Reimagining early-stage drug discovery leveraging NVIDIA BioNeMo Framework -- Persistent Systems (BSE: 533179) (NSE: PERS...
The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel genomic data from over 100 million new species...
Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a trans...
New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J. Fo...
- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosu...
23andMe, a leading consumer genetics and research organization and nonprofit affiliate of the 23andMe Research Institute, today announced the launch of a...
© 2026 Biopharma Boardroom. All Rights Reserved.
